The
Delhi High Court has ruled against
Roche in favour of
Cipla citing public interest, reports CNBC-TV18. It ruled that Cipla couldn’t be refrained from manufacturing Roche's
Tarceva. Cipla can restart production with immediate effect, the High Court said.
